Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label Study Employing the Topical Immunomodulator Diphencyprone to Treat Cutaneous Neurofibromas Associated With NF1

NCT05438290 is registered in ClinicalTrials.gov with Nicholas Gulati as lead sponsor.

NCT NCT05438290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05438290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label Study Employing the Topical Immunomodulator Diphencyprone to Treat Cutaneous Neurofibromas Associated With NF1
Lead sponsor
Nicholas Gulati
Phase
Phase 1
Overall status
Completed
Start date
September 14, 2022
Completion date
May 17, 2023
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous neurofibroma